DURECT CORP. DL-001
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment… Read more
DURECT CORP. DL-001 (DC8A) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, DURECT CORP. DL-001 (DC8A) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
DURECT CORP. DL-001 - Net Assets Trend (None–None)
This chart illustrates how DURECT CORP. DL-001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for DURECT CORP. DL-001 (None–None)
The table below shows the annual net assets of DURECT CORP. DL-001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to DURECT CORP. DL-001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
DURECT CORP. DL-001 Competitors by Market Cap
The table below lists competitors of DURECT CORP. DL-001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SYN-Tech Chem & Pharm Co Ltd
TWO:1777
|
$45.00 Million |
|
Accuray Incorporated
NASDAQ:ARAY
|
$45.01 Million |
|
SunWay Biotech Co., LTD.
TWO:1271
|
$45.04 Million |
|
Southern Rubber Industry JSC
VN:CSM
|
$45.04 Million |
|
IF Bancorp Inc
NASDAQ:IROQ
|
$44.99 Million |
|
Multitude SE
LSE:0R4W
|
$44.97 Million |
|
GAMING INNOVATION DL 1
F:GI11
|
$44.96 Million |
|
Medexus Pharmaceuticals Inc
OTCQX:MEDXF
|
$44.95 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DURECT CORP. DL-001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares DURECT CORP. DL-001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently DURECT CORP. DL-001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares DURECT CORP. DL-001's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DURECT CORP. DL-001 (DC8A) | €- | N/A | N/A | $44.99 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |